U.S. flag An official website of the United States government
  1. Home
  2. Advisory Committees
  3. Committees and Meeting Materials
  4. Human Drug Advisory Committees
  5. Arthritis Advisory Committee
  6. Waiver for Conflicts of Interest for the April 24-25, 2018 Joint Meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM)
  1. Human Drug Advisory Committees

Waiver for Conflicts of Interest for the April 24-25, 2018 Joint Meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM)

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance

 
Disclaimer
 
The Food and Drug Administration Amendments Act of 2007 (FDAAA), enacted on September 27, 2007, added a new provision regarding financial conflicts of interest, § 712 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), effective October 1, 2007. Accordingly, for advisory committee meetings after October 1, 2007, FDA is granting waivers under 18 U.S.C. § 208 and § 712 of the FD&C Act, where applicable, when the relevant waiver standards in these statutes are met.
 
Waivers under 21 U.S.C. § 355(n)(4) were issued before October 1, 2007.  This provision was repealed, effective October 1, 2007, by the FDA.

 

Ruth Parker, M.D.


Contact Information

FDA Advisory Committee Information Line
1-800-741-8138
(301-443-0572 in the Washington DC area)

Please call the Information Line for up-to-date information on this meeting.